Patents by Inventor Jürgen Krauss
Jürgen Krauss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220169705Abstract: Described is an anti-HSV antibody or an antigen-binding fragment thereof for use in treating an acute infection of mucosal or epidermal tissue in a subject caused by HSV-1 or HSV-2 selected from the group consisting of Herpes simplex labialis, Herpes simplex genitalis, chronic or disseminated cutaneous herpes simplex infection, Herpes gladiatorum and Eczema herpeticum, wherein said antibody is to be topically administered as well as to a pharmaceutical composition comprising an effective amount of said antibody or antigen-binding fragment thereof and at least one pharmaceutically acceptable excipient.Type: ApplicationFiled: February 18, 2022Publication date: June 2, 2022Applicant: Heidelberg ImmunoTherapeutics GmbHInventors: Michaela Arndt, Jürgen Krauss, Dirk Jäger
-
Patent number: 11267871Abstract: Described is an anti-HSV antibody or an antigen-binding fragment thereof for use in treating an acute infection of mucosal or epidermal tissue in a subject caused by HSV-1 or HSV-2 selected from the group consisting of Herpes simplex labialis, Herpes simplex genitalis, chronic or disseminated cutaneous herpes simplex infection, Herpes gladiatorum and Eczema herpeticum, wherein said antibody is to be topically administered as well as to a pharmaceutical composition comprising an effective amount of said antibody or antigen-binding fragment thereof and at least one pharmaceutically acceptable excipient.Type: GrantFiled: June 25, 2015Date of Patent: March 8, 2022Assignee: Heiselberg ImmunoTherapeutics GmbHInventors: Michaela Arndt, Jürgen Krauss, Dirk Jäger
-
Patent number: 10442863Abstract: Described is a construct comprising (a) a targeting moiety; (b) a fusogenic moiety consisting one or more fusogenic sequence(s) derived from dengue virus glycoprotein E comprising the sequence DRGWGNGCGLFGKGGI (SEQ ID NO:1) or a sequence which shows 1 to 8 substitutions, deletions, or insertions in comparison to SEQ ID NO:1; and (c) a molecule which is to be delivered into the cytoplasm of a cell. Moreover, described is a pharmaceutical composition comprising the construct according to the invention and optionally a pharmaceutical acceptable carrier. Further, described is a kit comprising one or more fusogenic sequence(s) derived from dengue virus glycoprotein E comprising the sequence as shown in SEQ ID NO:1 or a sequence which shows 1 to 8 substitutions, deletions, or insertions in comparison to SEQ ID NO:1.Type: GrantFiled: September 7, 2015Date of Patent: October 15, 2019Assignee: Lutana GMBHInventors: Michaela Arndt, Jürgen Krauss, Stefan Kiesgen
-
Publication number: 20170260274Abstract: Described is a construct comprising (a) a targeting moiety; (b) a fusogenic moiety consisting one or more fusogenic sequence(s) derived from dengue virus glycoprotein E comprising the sequence DRGWGNGCGLFGKGGI (SEQ ID NO:1) or a sequence which shows 1 to 8 substitutions, deletions, or insertions in comparison to SEQ ID NO:1; and (c) a molecule which is to be delivered into the cytoplasm of a cell. Moreover, described is a pharmaceutical composition comprising the construct according to the invention and optionally a pharmaceutical acceptable carrier. Further, described is a kit comprising one or more fusogenic sequence(s) derived from dengue virus glycoprotein E comprising the sequence as shown in SEQ ID NO:1 or a sequence which shows 1 to 8 substitutions, deletions, or insertions in comparison to SEQ ID NO:1.Type: ApplicationFiled: September 7, 2015Publication date: September 14, 2017Inventors: Michaela Arndt, Jürgen Krauss, Stefan Kiesgen
-
Publication number: 20170152304Abstract: Described is an anti-HSV antibody or an antigen-binding fragment thereof for use in treating an acute infection of mucosal or epidermal tissue in a subject caused by HSV-1 or HSV-2 selected from the group consisting of Herpes simplex labialis, Herpes simplex genitalis, chronic or disseminated cutaneous herpes simplex infection, Herpes gladiatorum and Eczema herpeticum, wherein said antibody is to be topically administered as well as to a pharmaceutical composition comprising an effective amount of said antibody or antigen-binding fragment thereof and at least one pharmaceutically acceptable excipient.Type: ApplicationFiled: June 25, 2015Publication date: June 1, 2017Inventors: Michaela Arndt, Jürgen Krauss, Dirk Jäger
-
Patent number: 9657088Abstract: The invention relates to an anti-HSV antibody as defined in the claims, a pharmaceutical composition comprising of an effective amount of the said antibody, an expression vector comprising of a nucleotide sequence which encodes the said antibody, a host cell comprising of the said nucleotide sequence, a hybridoma cell capable of producing the said antibody and the use of the said antibody as a drug, in particular to use for the manufacture of a drug for the prophylactical or therapeutical treatment of HSV-associated diseases in a subject; as defined in the claims.Type: GrantFiled: November 17, 2014Date of Patent: May 23, 2017Assignee: Heidelberg ImmunoTherapeutics GmbHInventors: Michael Roggendorf, Anna-Maria Eis-Hübinger, Jürgen Krauss, Karl Eduard Schneweis, Michaela Arndt, Adalbert Krawczyk, Evelyn Exner, Martin P. Däumer
-
Publication number: 20150166638Abstract: The invention relates to an anti-HSV antibody as defined in the claims, a pharmaceutical composition comprising of an effective amount of the said antibody, an expression vector comprising of a nucleotide sequence which encodes the said antibody, a host cell comprising of the said nucleotide sequence, a hybridoma cell capable of producing the said antibody and the use of the said antibody as a drug, in particular to use for the manufacture of a drug for the prophylactical or therapeutical treatment of HSV-associated diseases in a subject; as defined in the claims.Type: ApplicationFiled: November 17, 2014Publication date: June 18, 2015Inventors: Michael ROGGENDORF, Anna-Maria Eis-Hübinger, Jürgen Krauss, Karl Eduard Schneweis, Michaela Arndt, Adalbert Krawczyk, Evelyn Exner, Martin P. Däumer
-
Patent number: 8889137Abstract: The invention relates to an anti-HSV antibody as defined in the claims, a pharmaceutical composition comprising of an effective amount of the said antibody, an expression vector comprising of a nucleotide sequence which encodes the said antibody, a host cell comprising of the said nucleotide sequence, a hybridoma cell capable of producing the said antibody and the use of the said antibody as a drug, in particular to use for the manufacture of a drug for the prophylactical or therapeutical treatment of HSV-associated diseases in a subject; as defined in the claims.Type: GrantFiled: October 1, 2010Date of Patent: November 18, 2014Assignees: Universität Duisberg Essen, Rheinische Friedrich Wilhelms —Universität BonnInventors: Michael Roggendorf, Anna-Maria Eis-Hübinger, Jürgen Krauss, Karl Eduard Schneweis, Michaela Arndt, Adalbert Krawczyk, Evelyn Exner, Martin P. Däumer, Edelgard Schneweis
-
Patent number: 8425265Abstract: An arrangement for fastening an electrical conductor has a clamp (1) constructed as a pipe piece of metal and at least one clamping screw (2) for fastening an electrical conductor (3,4) in the clamp. The clamp has in its wall at least one throughhole provided with a thread for receiving the clamping screw. The clamping screw has a tubular contact part provided with an external thread and adapted to be screwed into the throughhole of the clamp, wherein the contact part has at its one axial end a contact surface for contacting an electrical conductor located in the clamp and along its extension with a circumferential intended breaking point a significant distance from the contact surface.Type: GrantFiled: January 26, 2012Date of Patent: April 23, 2013Assignee: NexansInventors: Gert Stauch, Volker Markgraf, Juergen Krauss, Manfred Baesch, Martin Zapf, Rainer Seebauer
-
Publication number: 20130058952Abstract: The invention relates to an anti-HSV antibody as defined in the claims, a pharmaceutical composition comprising of an effective amount of the said antibody, an expression vector comprising of a nucleotide sequence which encodes the said antibody, a host cell comprising of the said nucleotide sequence, a hybridoma cell capable of producing the said antibody and the use of the said antibody as a drug, in particular to use for the manufacture of a drug for the prophylactical or therapeutical treatment of HSV-associated diseases in a subject; as defined in the claims.Type: ApplicationFiled: October 1, 2010Publication date: March 7, 2013Inventors: Michael Roggendorf, Anna-Maria Eis-Hübinger, Jürgen Krauss, Karl Eduard Schneweis, Edelgard Schneweis, Michaela Arndt, Adalbert Krawczyk, Evelyn Exner, Martin P. Däumer
-
Publication number: 20120202393Abstract: An arrangement for fastening an electrical conductor has a clamp (1) constructed as a pipe piece of metal and at least one clamping screw (2) for fastening an electrical conductor (3,4) in the clamp. The clamp has in its wall at least one throughhole provided with a thread for receiving the clamping screw. The clamping screw has a tubular contact part provided with an external thread and adapted to be screwed into the throughhole of the clamp, wherein the contact part has at its one axial end a contact surface for contacting an electrical conductor located in the clamp and along its extension with a circumferential intended breaking point a significant distance from the contact surface.Type: ApplicationFiled: January 26, 2012Publication date: August 9, 2012Inventors: Gert Stauch, Volker Markgraf, Juergen Krauss, Manfred Baesch, Martin Zapf, Rainer Seebauer
-
Publication number: 20100216772Abstract: The present invention relates to compounds of the general formula (IV) and (II) and salts and physiologically functional derivatives thereof, wherein X is C—R8 or N; and Z is independently one of the following groups:Type: ApplicationFiled: October 5, 2004Publication date: August 26, 2010Inventors: Stefano Pegoraro, Martin Lang, Juliane Feurle, Jürgen Krauss
-
Patent number: 7456260Abstract: The current invention provides new human variable chain framework regions and humanized antibodies comprising the framework regions. The invention also provides a new method of identifying framework acceptor regions in framework sequences for backmutation to graft a donor sequence to the human framework.Type: GrantFiled: June 17, 2003Date of Patent: November 25, 2008Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, The University of ReadingInventors: Susanna M. Rybak, Juergen Krauss, Michaela Arndt, Andrew C. R. Martin
-
Publication number: 20060193849Abstract: A modified antibody molecule which selectively binds to a specific target, the antibody molecule being modified at at least one amino acid residue that determines antigen binding selectivity and/or affinity, characterised in that the modified antibody molecule exhibits a greater stability than an unmodified parent antibody molecule which selectively binds to the target. Also described are nucleotide sequences encoding, vectors, host cells and composition containing and uses of such antibodies, antibody fragments or antibody derivatives.Type: ApplicationFiled: February 25, 2005Publication date: August 31, 2006Inventors: Juergen Krauss, Nigel Courtenay-Luck, Susanna Rybak